Thomson StreetEvents

...Jawad Hasan - UBS - Analyst Good morning and thank you again for attending the #### UBS Global Life Sciences conference. My name is Jawad Hasan, and I am happy to be your host for this session. Our next presentation is from Dr. Ben Yerxa, Executive Vice President and Chief of Research and Development at Inspire Pharmaceuticals. Immediately following the presentation, there will be a breakout session in the [Alvin] room, directly one floor below. Thank you. Ben Yerxa - Inspire Pharmaceuticals - EVP, Chief of Research and Development Thank you, and good morning, everyone. I am Ben Yerxa. I'm the head of R&D for Inspire Pharmaceuticals and I'm glad to be here today at the UBS Global Life conference to tell you a little bit more about Inspire. Quick one on myself. I've been with the Company for about ## years and have been able to see some of our science go from idea all the way into Phase III. And so, I will be telling you about some of those programs today. But before I get into the details...

... - IR Angela Chen Pericom Semiconductor Corporation - CFO Alex Hui Pericom Semiconductor Corporation - President and CEO C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Lasse Glassen Financial Relations Board - IR Bill Gervais Qualstar Corporation - President, CEO Nicki Andalon Qualstar Corporation - CFO C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Robert Bennett - Analyst Justin Foster - Analyst Steven Waller - Analyst Dave Holmes - Analyst Eric Button - Analyst Samir Fenantinel - Analyst P R E S E N T A T I O N...

...Unidentified Participant Good afternoon and, again, thank you for attending the #### Global Life Sciences Conference. This afternoon we have the pleasure of hearing from Michael Tokich, who is the Chief Financial Officer of STERIS. I just want to remind you that after his presentation there will be a breakout in the Juilliard room which will be one floor below here. Thanks very much. Michael. Michael Tokich - STERIS Corporation - CFO, PAO, SVP Good afternoon, everybody. How are you today? We are here to talk about STERIS Corporation. Once again my name is Michael Tokich. I am the CFO. I'm going to start with a brief overview of our Corporation. But before I do that my attorneys would not be happy unless I told you that I have to caution that I may be making forward-looking statements and they are accurate only as of today. So please check our SEC filings for more detailed disclosures. So with that, I'm going to spend my time walking through our business, including details of our reporting...

...Karl Mahler Roche Holding AG - Head of IR Sandra Horning R o c h e H o l d i n g A G - SVPandGlobalHeadofClinicalDevelopmentOncology/HematologyandHeadoftheDiseaseBiologyLeadershipTeam Varun Nanda Roche Holding AG - Global Product Strategy, Head Oncology Philippe Bishop Roche Holding AG - VP, Clinical Development, Avastin Niko Andre Roche Holding AG - Global Medical Director, Avastin Franchise Stefan Frings Roche Holding AG - Global HER# Franchise Leader CONFERENCE CALL PARTICIPANTS...

...Jeffrey Mezger KB Home - President, CEO Bill Hollinger KB Home - SVP, Chief Accounting Officer Kelly Masuda KB Home - SVP and Treasurer CONFERENCE CALL PARTICIPANTS...

...Nikhil Patel Good morning, everyone. Thank you for joining the #### UBS Global Life Sciences Conference. My name is Nikhil Patel. I will be your host for this session. It is my distinct pleasure to introduce to you Alfred Mann, Chairman and CEO of MannKind Corporation. I would just like to give everyone a quick reminder, there will be a ##-minute breakout session immediately following this. This will be in the Yuris Conference Room, which is one level below. Thank you. Alfred Mann Good morning, ladies and gentlemen. Thank you all for joining us today. We are going to talk a little bit about MannKind, and we will concentrate on our diabetes program, but we are a company that is dedicated to diabetes endocrinology and also oncology. I'm just going to say very briefly that our work in our -- we have two of our cancer vaccines in the clinic, and in particular, the melanoma vaccine is looking very exciting. It is only Phase I/II studies but the results are really quite remarkable. Nobody cares...

... Welcome to the #### UBS Global Life Sciences Conference. My name is (inaudible) Patel. I'll be your host for thesession.It'smydistinctpleasurerightnowtointroducetoyouTedSchroeder,CEOandPresidentofCadencePharmaceuticals. A quick reminder to everyone. There will be a ##-minute breakout session immediately following the presentation, and that will be in the Uris conference room, which is one level below. Thank you. Ted Schroeder - Cadence Pharmaceuticals, Inc. - President and CEO Thank you. Thanks for inviting us to the conference and thanks to each of you for attending. There's nothing better than not having any place for you to sit at lunch than come in here. So I appreciate the strategy of the bank driving attendance. Subject you to the forward-looking statement before we get started here, and just to remind everyone that we may be talking about some forward-looking statements. I would caution you not put undue reliance on those statements,...

...Steve Shrewsbury AVI BioPharma - Chief Medical Officer and SVP Preclinical, Clinical and Regulatory Affairs P R E S E N T A T I O N...

...Cici Zheng - UBS - Analyst Good afternoon, and thank you again for attending the UBS global life sciences conference. My name is Cici Zheng, and I'm happy that introduce our next two speakers. Dr. Frank Witney, President and CEO; and Craig McCollam, Executive Vice President and CFO, of Dionex Corporation. Following this presentation there will be a breakout session in the Juilliard Room downstairs. Frank Witney - Dionex Corporation - President and CEO Good afternoon everyone. I want to thank USB for the opportunity to present Dionex. This presentation may contain forward-looking statements that may or may not occur based on various factors as shown on the slide. The agenda for today is I'm going to give a brief business overview, then talk a little bit about our strategy and the progress we've made against our goals on our implementation of that strategy. Then I'm going to turn it over to Craig McCollam, our [EVP] and CFO, who will walk you through our financials and give you our outlook...

...Dan Arias - UBS - Analyst Good morning. Welcome to the #### UBS Global Life Sciences Conference. My name is Dan Arias. I am an associate on the Life Sciences Tools Research team. At this time it is my pleasure to introduce to you Kathy Ordonez, Chief Executive Officer of Celera Corporation. Immediately following the presentation we will have a breakout session in the Carnegie room. Kathy Ordonez - Celera - CEO Thank you, Dan, and good morning, everyone. Thanks for attending this session so early today. I am going to be talking about Celera Corporation and I will be making some forward-looking statements that have associated risks and uncertainties. Hopefully you are familiar with Celera. We are the company that sequenced the human genome and published the draft sequence in early ####. And I would like to take just a moment to point out that President Obama is going to be awarding the National Medal of Science to Craig Venter and to Francis Collin on October # to celebrate this achievement....

...Karl Mahler Roche Holding AG - Head of IR Sandra Horning Roche Holding AG - SVP and Global Head of Clinical Development Oncology/Hematology and Head of the Disease Biology Leadership Team Varun Nanda Roche Holding AG - Global Product Strategy, Head Oncology Philippe Bishop Roche Holding AG - VP, Clinical Development, Avastin Niko Andre Roche Holding AG - Global Medical Director, Avastin Franchise Stefan Frings Roche Holding AG - Global HER# Franchise Leader C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Unidentified Participant Good morning and welcome again to the #### UBS Global Life Sciences Conference. My name is (inaudible) it's my pleasure to introduce our next speaker, Stephen Willard, Chief Executive Officer of Flamel Technologies. Following his presentation, there will be a breakout session in the Juilliard room downstairs. Thank you. Stephen Willard - Flamel Technologies - CEO Thank you very much for that introduction. Because we are a US public company, we encourage you to carefully review all of our securities law filings which are available on our website. Flamel is a polymer chemistry company that specializes in drug delivery. We make existing drugs better and our platforms can also be used to remove roadblocks to develop for promising drugs that have formulation drawbacks. In both cases, our partners have come to recognize the tremendous value that can be created by drug delivery solutions. Flamel is having a really great year. We are just beginning to enjoy the fruits of...

...Alan Herrick Sapient Corp - Chief Executive Officer, President Chip Register Sapient Corp - Senior Vice President, Managing Director Gaston Legorburu Sapient Corp - Executive Director and Worldwide Creative Officer Michael Leonard Sapient Corp - Program Management Joe Tibbetts Sapient Corp - SVP and CFO P R E S E N T A T I O N...

... Our next presenter is Cesar Garcia, Chairman, President and CEO of IRIS International. Immediately after his presentation, the breakout session is in the [Alden] room at the conference level. Cesar Garcia - IRIS International - Chairman, President, CEO Good afternoon everyone. I have a challenge of keeping you awake after your lunch. So let me talk about IRIS. IRIS is a profitable IVD company. We have been in business for a long time, but really our success began in #### with the launch of a new product platform called the iQ###. So we are capitalizing on our success and we are expanding our product pipeline into large addressable markets. So our success has been in the core business of automated urinalysis. Urinalysis is a high-volume, low investment business. It has been very good for us. But at the same time, we decided in #### that we wanted to diversify into high-value segments. So we are concentrating on diversification, developing...

...Operator This conference is being recorded. All conference participants are muted. Kelvyn Cullimore - Dynatronics Corporation - President, CEO Kelvyn Cullimore, President and CEO of Dynatronics Corporation. We welcome you to our conference call to report earnings for the fourth fiscal quarter of fiscal year #### and year-end results. The purpose of today's conference call is to discuss the financial results for the quarter and year ended June ##, ####. And before webegin,asareminder,duringthecourseofthisconferencecallmanagementmaymakeforward-lookingstatementsregarding future events or the future financial performance of the Company. Those statements involve risks and uncertainties that could cause actual results to differ, perhaps materially, from the results projected in such forward-looking statements. We caution you that any such statements should be considered in conjunction with the disclosures, including specific risk factors and financial data contained in the Company's most recent...

...Ed Wilhelm Finish Line - CFO Glenn Lyon Finish Line - CEO Steve Schneider Finish Line - President, COO Sam Sato Finish Line - Chief Merchandising Officer CONFERENCE CALL PARTICIPANTS...

...Jeffrey Mezger KB Home - President, CEO Bill Hollinger KB Home - SVP, Chief Accounting Officer Kelly Masuda KB Home - SVP and Treasurer C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Nikita Patel - UBS - Analyst Hello everyone. Good morning and welcome to the #### UBS global life sciences conference. My name is Nikita Patel. I'm happy tobeyourhostforthissession.It'smypleasurenowtointroducetoyouDougMichels,PresidentandCEOofOraSureTechnologies. Just a quick reminder to everybody, we will have a breakout session immediately following this, and that will be in the Uris Ballroom, which is one floor below. Thanks. Doug Michels - OraSure Technologies, Inc. - President and CEO Good morning everyone, and thank you for joining us this morning. I am joined here this morning by my Chief Operating Officer and Chief Financial Officer, Ron Spair, as well. This morning, before I get into the presentation, as you all know, we will be making some forward-looking statements. And obviously any future projections come with risks. We encourage you to refer to the company's SEC filings, ##-K and ##-Q, for a more in-depth description of those factors that might affect future performance. A...

...Brian Shore Park Electrochemical Corp. - President & CEO Matt Farabaugh Park Electrochemical Corp. - VP, Controller, PFO & PAO C O N F E R E N C E C A L L P A R T I C I P A N T S...

... to the #### UBS Global Life Sciences conference. Our next presenter is Stephen Webster, Senior Vice President and Chief Financial Officer from Adolor. Please note that the breakout session will be held immediately following the presentation downstairs in the Euris Room. Stephen Webster - Adolor Corporation - SVP & CFO Great. Thank you very much. I appreciate everyone's perseverance here late in the day on the last day of the conference. We kind of had a little over and under going and I'm happy to say the attendance is over what we thought. Also, thanks to UBS for having us up. I am going to share the podium today with my colleague, Eliseo Salinas, our Chief Medical Officer, who will walk you through a couple of the development programs after I give you a quick overview and talk about our first commercial product, Entereg. You've probably been reading these all day. Again, please no undue reliance on any forward-looking statements, but we...

...Cici Zheng UBS - Analyst/Moderator Sam Riccitelli Genoptix - EVP, COO Marcy Graham Genoptix - Senior IR Director P R E S E N T A T I O N...

...Unidentified Participant Good morning and welcome to the second day of UBS Global Life Sciences Conference. I'm Erik Schneider and together with Bruce Nudell, we cover the US medical device space. It is my pleasure this morning to introduce Thoratec's CFO, David Smith, to speak about the Company. As a reminder, please save your questions for the breakout session immediately following in the Carnegie room. David? David Smith - Thoratec Corporation - CFO Thank you Erik. I want to thank UBS for asking us to speak at the conference and thank you for your attendance this morning. #### has been a very exciting year for Thoratec. It's been a great build year off of the excitement of launching HeartMate II for bridge to transplantation in ####. I'll spend a little bit of time talking about the balance of #### and the excitement we see going forward. But no presentation is complete without a forward-looking statement. I direct you to our [## Act] filings with the SEC. We will be making forward-looking...

...Joe Dorame AZZ incorporated - IR- Lytham Partners David Dingus AZZ incorporated - President and CEO Dana Perry AZZ Incorporated - CFO C O N F E R E N C E C A L L P A R T I C I P A N T S...

...HIV-associated neuropathy. And if you file in Europe with two different models of neuropathic pain, you are eligible for a broad label, and you can see that we were able to accomplish that. In the United States, the regulators take a different approach and think that each neuropathic pain syndrome is a new entity. So you need replica trials in each indication that you apply for. In this case, we had two successful Phase III trials and post-hepatic neuralgia. That file was accepted in December of ####. Our original PDUFA date was August ##. That was extended for three months. I will talk a little bit about that later but we are now on track for a PDUFA date of November ##. I am not going to spend a lot of time later on talking about some earlier stage programs that we have, but we do have a robust pipeline that we are kind of excited about. I'll show you just a little bit of data on one of these products that is an acetaminophen prodrug, and we have all read the headlines coming out of the...

...Monique Greer Allos Therapeutics, Inc. - VP of IR Paul Berns Allos Therapeutics, Inc. - President and CEO Pablo Cagnoni Allos Therapeutics, Inc. - SVP and CMO Jim Caruso Allos Therapeutics, Inc. - EVP and CCO C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Stephen Green HSBC Holdings Plc - Group Chairman Michael Geoghegan HSBC Holdings Plc - Group Chief Executive Douglas Flint HSBC Holdings Plc - Group Finance Director C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Chris McLeish Tate & Lyle plc - Director, Investor & Media Relations Iain Ferguson Tate & Lyle plc - Chief Executive Tim Lodge Tate & Lyle plc - Group Finance Director CONFERENCE CALL PARTICIPANTS...

...Stephen Green HSBC Holdings Plc - Group Chairman Michael Geoghegan HSBC Holdings Plc - Group Chief Executive Douglas Flint HSBC Holdings Plc - Group Finance Director CONFERENCE CALL PARTICIPANTS...

...Kevan Bloomgren Media Sciences International, Inc. - CFO Michael Levin Media Sciences International, Inc. - Founder, President, CEO C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Ed Wilhelm Finish Line - CFO Glenn Lyon Finish Line - CEO Steve Schneider Finish Line - President, COO Sam Sato Finish Line - Chief Merchandising Officer C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Operator Good morning and welcome to today's Lyris fourth quarter fiscal #### earnings conference call. As a reminder, today's call is being recorded. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given on how to participate at that time. (Operator Instructions) I'd now like to turn the call over to Mr. Richard McDonald, the Company's Director of Investor Relations. Please go ahead, sir. Richard McDonald - Lyris, Inc. - Director - IR Thank you and hello, everyone. With me today are Luis Rivera, our Company's Chief Executive Officer, and Heidi Mackintosh, Vice President and Chief Financial Officer. BeforeIturnthecallovertoLuis,itshouldbenotedthatduringthecourseoftoday'sconferencecallandthequestion-and-answer session that follows, we may make projections or other forward-looking statements that are subject to the Safe Harbor provisions of the securities laws regarding future events or financial performance...

...Chris McLeish Tate & Lyle plc - Director, Investor & Media Relations Iain Ferguson Tate & Lyle plc - Chief Executive Tim Lodge Tate & Lyle plc - Group Finance Director C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Adele Ebbs Research In Motion Limited - VP IR Jim Balsillie Research In Motion Limited - Chairman, Co-CEO Brian Bidulka Research In Motion Limited - CAO Gus Papageorgiou Research In Motion Limited - Analyst CONFERENCE CALL PARTICIPANTS...

...John DiFucci JP Morgan - Analyst Mark Murphy Piper Jaffray - Analyst Brad Zelnick Macquarie - Analyst Nabil Elsheshai Pacific Crest Securities - Analyst Yun Kim Broadpoint Amtech - Analyst Geo Joan Goldman Sachs - Analyst Tim Klassel Thomas Weisel Partners - Analyst Kash Rangan Merrill Lynch - Analyst David Hilal FBR - Analyst Brent Williams Benchmark - Analyst OVERVIEW...

...Jean Fontana Christopher & Banks - Integrated Corporate Relations Lorna Nagler Christopher & Banks - President, CEO Rodney Carter Christopher & Banks - EVP, CFO Monica Dahl Christopher & Banks - SVP, Planning & Allocation, e-Commerce CONFERENCE CALL PARTICIPANTS...

...A. Highlights: #. Revenue, $##.#m. a. Up #% vs. $##.#m in #Q##. #. License and OnDemand revenues from sales of unified people management solutions, $##m. a. Significant increase of ##% from #Q##. #...

...John Wright - Petrominerales Ltd. - President, CEO and Director Thanks, Martin, and a special thanks to FirstEnergy and Societe Generale for this opportunity to tell the Petrominerales story. You can read our lawyer's message at your leisure. We've got a pretty big presentation here, and I'd really like to hit a bunch of the highlights and answer as many questions as possible. To set the stage, Petrominerales in #### was spun out of Petrobank through an IPO process. Currently, we've got slightly less than ### million shares outstanding; carry a market cap today of about $#.## billion. Mostrecentquarter,weannouncedweaveragedabout##,###barrelsofoilperday.Mostrecently,we'vehadrecentproduction levels in the ##,### barrel a day range. And I hate to be repetitive, and it's a tough act to follow to come after [Dino] with all his exploration story, but we have a very similar growth program as some of the other Canadian players who have taken on in Colombia. Our idea is pretty simplistic. We've...

...Linda English Texas Industries - Manager, IR Mel Brekhus Texas Industries - President, CEO Ken Allen Texas Industries - VP - Finance, CFO CONFERENCE CALL PARTICIPANTS...

...Adele Ebbs Research In Motion Limited - VP IR Jim Balsillie Research In Motion Limited - Chairman, Co-CEO Brian Bidulka Research In Motion Limited - CAO Gus Papageorgiou Research In Motion Limited - Analyst C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Mark Namaroff Analogic Corporation - Director, IR Jim Green Analogic Corporation - President, CEO Mike Levitz Analogic Corporation - VP, CFO, Treasurer C O N F E R E N C E C A L L P A R T I C I P A N T S...

...John DiFucci JP Morgan - Analyst Mark Murphy Piper Jaffray - Analyst Brad Zelnick Macquarie - Analyst Nabil Elsheshai Pacific Crest Securities - Analyst Yun Kim Broadpoint Amtech - Analyst Geo Joan Goldman Sachs - Analyst Tim Klassel Thomas Weisel Partners - Analyst Kash Rangan Merrill Lynch - Analyst David Hilal FBR - Analyst Brent Williams Benchmark - Analyst P R E S E N T A T I O N...

...Operator Welcome to Spectrum Control Inc.'s #### third quarter conference call. Representing the Company today we have Dick Southworth, President and Chief Executive Officer; and Jack Freeman, Senior Vice President and Chief Financial Officer. Their discussion of the Company's operating performance for the quarter ended August ##, #### should take about ## minutes. Theywillthentrytoanswerasmanyquestionsasreasonablypossible.Weexpecttoconcludethisconferencecallatapproximately #:## p.m. Eastern Time. As a reminder, the following discussion will include certain forward-looking statements which reflect management's current views with respect to future market conditions and operating performance. These forward-looking statements are subject to certain risks and uncertainties which could cause actual results to differ materially from historical results or those anticipated. These risks and uncertainties are described in detail in the Company's most recent quarterly and annual SEC filings. The...

...Jawad Hasan - UBS - Analyst Good afternoon. Thank you again for attending the #### UBS global life sciences conference. My name is Jawad Hasan, and I'd happy to be your host for this session. Our next presentation is from Friedhelm Blobel, who is the President and CEO of SciClone Pharmaceuticals. Immediately following the presentation there will be a breakout session in the Juilliard Room, directly one floor below. Friedhelm Blobel - SciClone Pharmaceuticals, Inc. - President, CEO and Director Good afternoon. First of all I would like to thank UBS for the opportunity to present today. And you are not surprised to see the Safe Harbor statement. I will be making some forward-looking statements today. So if you would like to have some more information about that, feel free to also take a look on our website. SciClone pharmaceuticals represents an attractive investment opportunity. We are a profit-driven enterprise and see ourselves as a speciality pharma company. We have solid global sales...

... Instructions) As a reminder today's conference call is being recorded. I'd now like to turn the conference over to Saba's Chief Financial Officer, Bill Slater. Please go ahead, sir. Bill Slater - Saba Software, Inc. - CFO Good afternoon and thank you for attending Saba Software's first quarter fiscal #### conference call. With me today is Chairman and Chief Executive Officer, Bobby Yazdani. If you have not received today's earnings release, you may download it at www.saba.com. During the course of this conference call we will be making forward-looking statements within the meaning oftheSecuritiesActof####andtheSecuritiesExchangeActof####,includingstatementsregardingSaba'sfutureperformance and financial projections, Saba's belief that first quarter professional service revenues hit a bottom, Saba's promising relationship with IBM including a growing pipeline and Saba's ability...

...Ralph Muller UBS - Analyst John Ogrodnick JP Turner - Analyst David Lavigne Accredited Members Inc. - Analyst Anki Dupka - Private Investor Dan Cromney - Private Investor P R E S E N T A T I O N...

...Lori Freedman pSivida Corp. - VP Corporate Affairs, General Counsel & Corporate Secretary Dr. Paul Ashton pSivida Corp. - President & CEO Len Ross pSivida Corp. - Principal Accounting Officer & Controller C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Jean Fontana Christopher & Banks - Integrated Corporate Relations Lorna Nagler Christopher & Banks - President, CEO Rodney Carter Christopher & Banks - EVP, CFO Monica Dahl Christopher & Banks - SVP, Planning & Allocation, e-Commerce C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Richard Chamberlain Banc of America-Merrill Lynch - Analyst Fraser Ramzan Nomura Securities - Analyst Robert Miller Redburn Partners - Analyst Andrew Hughes UBS - Analyst Anne Critchlow Societe Generale - Analyst Simon Irwin Liberum Capital - Analyst Nick Fharm SEB Enskilda - Analyst Tony Shiret Credit Suisse - Analyst Paul Smiddy HSBC - Analyst P R E S E N T A T I O N...

...Douade Hassan - UBS - Analyst Good afternoon and thank you again for attending the #### UBS Global Life Sciences Conference. My name is [Douade Hassan] and I am happy to be your host for the session. Our next presentation will be from Rick Shea, Chief Financial Officer of Momenta Pharmaceuticals. Immediately following the presentation, there will be a breakout session in the Juilliard room which is on the conference level directly a floor below. Thank you. Rick Shea - Momenta Pharmaceuticals, Inc. - CFO Thankyouverymuch.I'dliketodrawyourattentiontoourSafeHarborstatementsandintroduceyoutoMomentaPharmaceuticals located in Cambridge, Mass. The Company was founded in ####, based on technology developed over a ##-year period at MIT. Technology is addressing the analysis and characterization of complex mixtures, including polysaccharides, polypeptides and biologics. We have a pipeline that includes the generic drugs and novel drugs. Generic versions of Lovenox, Copaxone and follow-on biologics...

...John McCluskey Alamos Gold Inc. - President & CEO Jon Morda Alamos Gold Inc. - CFO Charles Tarnocai Alamos Gold Inc. - VP, Corporate Development C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Michael Klayko Brocade Communications Systems, Inc. - CEO Richard Deranleau Brocade Communications Systems, Inc. - CFO, VP-Finance Dave Stevens Brocade Communications Systems, Inc. - CTO Ian Whiting Brocade Communications Systems, Inc. - SVP of Worldwide Sales and Marketing C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Robert Engbinder Garden State Securities - Analyst Michael Dyat Dyat and Bohada - Analyst Steve Jacobs - Private Investor Steven Hart Heller Capital Partners - Analyst Steve Donovan - Private Investor P R E S E N T A T I O N...

...Jawad Hasan - UBS - Analyst Good afternoon and thank you again for attending the #### UBS Global Life Sciences Conference. My name is Jawad Hasan, and I'm happy to be your host for this session. Our next presentation is from Greg Schiffman, who is Chief Financial Officer of Dendreon Corporation. Immediately following the presentation, there will be a breakout session in the Juilliard Room directly one floor below. Thank you. Greg Schiffman - Dendreon - CFO & SVP Thank you very much. We're very pleased to be able to present here today at the UBS Life Science Conference, and we would like to thank the team at UBS for inviting us to their event. This presentation will include forward-looking statements that are subject to risks and uncertainties, and to find out more about Dendreon's specific risks and uncertainties, please reference our SEC filings. So, Dendreon is a biotech company with a specific product focus in the area of oncology. More specifically, we're looking to bring a first-in-class...

...Unidentified Participant Welcome to the #### UBS Global Life Sciences conference. It is my pleasure to introduce our next guest speaker, David Greene, PresidentofHarvardBioscience.PleasenotethattheQ&Asessionwillbehelddownstairsimmediatelyfollowingthepresentation in the Uris room. Thank you. David Green - Harvard BIoscience, Inc. - President Thank you, Lee, and thank you, UBS, for inviting me to this conference. I think this is the sixth or seventh time now I've presented this conference. So I'm going to tell you this afternoon about Harvard Bioscience, an overview of the Company from a financial and business point of view. It will surprise none of you that I will be making forward-looking statements this afternoon. It's an essential part of our ability to communicate what we think is going to happen in the future of the business. And I also will be using non-GAAP information. The non-GAAP operating results that we often discuss include things -- exclude, I should say, things like FAS ###...

...Xavier Rolet London Stock Exchange - Chief Executive Doug Webb London Stock Exchange - CFO Raffaele Jerusalmi London Stock Exchange - Director, Capital Markets Massimo Capuano London Stock Exchange - Director, Post Trade & Deputy CEO David Lester London Stock Exchange - Director, Information & Technology Services C O N F E R E N C E C A L L P A R T I C I P A N T S...

... to the #### UBS Global Life Sciences conference. Our next presenter is Kevin Gorman, President and CEO of Neurocrine Biosciences. Immediately after the presentation, the breakout session will be held in Uris room downstairs. Thank you. Kevin Gorman - Neurocrine Biosciences, Inc. - President and CEO Thank you, Lee, and thank you to UBS for giving us the opportunity to speak here today. Put in front -- I'll be making forward-looking statements, so I direct you to our recent SEC filings for all the risks that are involved. So we are in our first full day of fall and as we look back, it's been a very productive and very busy summer for Neurocrine. We got a lot accomplished. What I'm going to spend the vast majority of the time on is the accomplishments that we have made in our GnRH program to date. But I do want to take this opportunity to say that there was -- we put another compound into the clinic just a few weeks ago and that was our VMAT#...

...Nikheel Patel - UBS - Analyst Hello, everyone. Thank you for being here at the #### Global Life Sciences conference hosted by UBS. My name is [Nikheel], and I'm happy to be your host for this afternoon. It's now my pleasure to introduce to you Mr. Joseph Corasanti, who is the President and CEO of CONMED. Just a quick reminder toeveryone.ImmediatelyfollowingthispresentationwillbeaQ&Abreakoutsession,andthatwillbeheldinthe[Alvin]conference room one floor below. Joseph Corasanti - CONMED - President, CEO Thank you very much. I will be talking to you today for about ## minutes about CONMED. We'll talk about our products and our distribution and our plans for the future. And before we do, please take a look at our forward-looking statements paragraph. We've been around for quite a while, since ####. We are headquartered in Utica, New York. We develop a lot of surgical products and sell those products directly into operating rooms and hospitals throughout the country and around the world. We also...

...Gord Currie Gennum Corporation - SVP of Finance and Administration, CFO Franz Fink Gennum Corporation - President and CEO C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Operator Hello and welcome to the John Wiley & Sons investor meeting webcast. We have just a few announcements before we begin. The slides will advance automatically throughout the presentation. (Operator Instructions). I would now like to turn the call over to Mr. Brian Campbell, Director, Investor Relations. Brian Campbell - John Wiley & Sons, Inc. - Director, IR Goodmorning,everyone,andwelcometoJohnWiley&Sons'####investorconference.OnbehalfofWileycolleaguesworldwide, I want to thank you for joining us, those of you in the room as well as on the webcast. We have quite a turnout. At the conclusion of the presentation, we're going to have a Q&A session, so I just ask that you hold your questions until then. Also, if you could switch off all BlackBerrys and cell phones, that would be greatly appreciated. Without further ado, I would like to introduce Will Pesce, President and CEO. Will Pesce - John Wiley & Sons, Inc. - President and CEO Thank you, Brian. Good morning, everyone, and thank...

...Bob Labick CJS Securities - Analyst Tony Cristello BB&T Capital Markets - Analyst Bill Armstrong CL King & Associates - Analyst Scott Ciccarelli RBC Capital Markets - Analyst Craig Kennison Robert W. Baird & Company, Inc. - Analyst Scott Stember Sidoti & Company - Analyst Gary Prestopino Barrington Research Associates, Inc. - Analyst Jordan Hymowitz Philadelphia Financial - Analyst Justin Boisseau Gates Capital Management - Analyst OVERVIEW...

...Liz Hirsch Praxair, Inc. - Director - IR Ray Roberge Praxair, Inc. - SVP, CTO Amer Akhras Praxair, Inc. - VP - Hydrogen & Refinery Business Development, North American Industrial Gases Mark Weise Praxair, Inc. - Senior Director - Industrial, Food and Water Applications Technologies, Research and Development Dan Bonaquist Praxair, Inc. - Senior Corporate Fellow, Chief Scientist Pravin Mathur Praxair, Inc. - Director, Business Development, Steel and Combustion Markets, North American Industrial Gases Chris Guild Praxair, Inc. - Director, Business Development, Energy and Environmental Markets, North American Industrial Gases Brian Meredith Praxair Electronics - Global Business Development Manager, Photovoltaics Ben Glazer Praxair Inc. - Global Business Manager, Helium and Rare Gases Leo Buchakjian Praxair Surface Technologies Inc. - Director, Aviation Business Development Richard Jarrett Praxair Inc. - Director, Business Development, Food and Beverage/Pharmaceuticals, North American Industrial...

...Martin Molyneaux - FirstEnergy Capital Corporation - Analyst Okay, our next presenter is Gran Tierra Energy. Gran Tierra has producing assets in Colombia and Argentina, an impressive portfolio of exploration prospects in Colombia, Peru and Argentina. The highlight that should not be overlooked is Gran Tierra's very strong financial position. At the end of Q# ####, the Company had a cash balance of $### million. And as such, has enough cash to carry out its extensive exploration program. Here to tell us more is Dr. Dana Coffield, Founder, President and CEO of Gran Tierra. Dana Coffield - Gran Tierra Energy Inc. - Founder, President & CEO All right, thank you very much, Martin, and thank you to SocGen and FirstEnergy for inviting me to present today. Those of you who have been following Gran Tierra's story over the last four years will know the Company has come through several phases. The first couple of years of our life was focused primarily on exploration in, as Martin said, Colombia,...

...Jim Manuso SuperGen, Inc. - Chairman, President and CEO Michael McCullar SuperGen, Inc. - VP, Strategy and Operations C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Jeff Elliott - UBS - Analyst Good afternoon and welcome to the UBS Global Life Sciences Conference. I'm Jeff Elliott. I'm the small and mid-cap US biotech analyst here at UBS. It's my pleasure to introduce Arena Pharmaceuticals. With us today is Mr. Jack Lief, Chief Executive Officer. Immediately following the presentation there will be a breakout session downstairs in the Juilliard Room, so if you could please hold your questions until then. With that, I will turn it over to Jack. Jack Lief - Arena Pharmaceuticals, Inc. - Chairman, President & CEO Thank you, Jeff. I'd like to also thank UBS for inviting us to this conference. So I'll be telling you about the data that we've recently announced, the BLOSSOM study data and I will tell you why I believe that lorcaserin is approvable, represents a very significant commercial opportunity, and why this will be a first-line therapy for weight management. Before I do, I'd like to remind everybody that I will be making forward-looking statements....

...Linda English Texas Industries - Manager, IR Mel Brekhus Texas Industries - President, CEO Ken Allen Texas Industries - VP - Finance, CFO C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Ahmed Kirgy - UBS - Analyst Good afternoon, everyone, and thank you for coming to the #### UBS Global Life Sciences conference. My name is [Ahmed Kirgy] and I will be your host for the session. Our next presenter will be Scott Lamb, Chief Financial Officer from ICU Medical. A breakout session in the Broadway room will follow immediately after the presentation. Thank you. Scott Lamb - ICU Medical, Inc. - CFO Great, well I would like to thank all of those present here. I know it is a little difficult late in the afternoon to focus and stay awake. So I will try and do my best to do both. We are ICU Medical. This is our obligatory statement from our attorneys, any statement concerning management's expectations with respect to futureresultsisaforward-lookingstatementbaseduponthebestinformationcurrentlyavailabletomanagementandassumptions management believes are reasonable, but management does not intend the statement to be a representation as to future results. Future results are subject to the...

...Nikheel Patel Good afternoon and thank you, everyone, for being here to the #### UBS Global Life Sciences conference. My name is Nikheel Patel and I will be your host for the rest of the day. It'snowmypleasuretointroducetoyouMr.EdwardLanphier,PresidentandCEOofSangamo.Justaquickreminderforeveryone. We will have a breakout session immediately following the presentation, and that will be held in the [Alvin] conference room, which is a floor below. Thank you. Edward Lanphier Good afternoon. It's a pleasure to be here. Thank you for including Sangamo in this year's conference. My presentation will contain forward-looking statements, and I'd like to refer you to our Forms ##-K and ##-Q filed with the SEC. Today is actually an interesting day for us. Some of you may know we announced the expansion of our HIV program, and so this presentation is actually going to focus fairly heavily not just on that new trial that we announced but on that entire area for us, and so for the first time really present...

...Kip Hallman InSight Health Services Holdings Corp. - Pres, CEO Keith Kelson InSight Health Services Holdings Corp. - EVP, CFO C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Darren Engels - FirstEnergy Capital Corporation - Analyst OurnextpresenterisVermilionEnergyTrust.HeretopresentisMr.BobMacDougall,ExecutiveVicePresidentandChiefOperating Officer.Forthoseofyouwhoknow,Vermilionrecentlygotincludedinourinternationalspace,givingitsweightingtointernational assets, both reserves and production and they've had a very busy year this year. The Corrib Gas Field acquisition, not to mention a little Verenex disposition with them being ##% owners of the company. Bob, please take it away. Bob Mac Dougall - Vermilion Energy Trust - EVP & COO Yes, so this story is going to be a little different than maybe what you've heard so far today. It's a good story. As Darren said, I'm Bob, I am the operations guy for Vermilion. What that means is I'm kind of the underpromise/overdeliver guy when it comes to operational performance and to be a little bit conservative. I feel a little bit out of place up here talking about -- talking with some of these presentations this morning. But...

...Mikael Doepel - UBS - Analyst Hello, everyone. Welcome to the third day of the #### UBS Global Life Sciences Conference. My name is Mikael Doepel. I am your host for today. It is now my pleasure to introduce to you Sabrina Johnson, who is the Chief Operating Officer, as well as the Chief Financial Officer for Cypress Bioscience. A quick reminder to everyone. There will be a breakout session immediately following the presentation, and that will be held in the Alvin Conference Room, which is a floor below where we are. Thank you. Sabrina Johnson - Cypress Bioscience - COO & CFO Thank you for the introduction, and thanks to UBS for having us here, and thanks all of you for being in the room. I know you have choices this morning, so we appreciate you being here. Before I start on the presentation, a quick reminder that it will contain forward-looking statements, and therefore, I would encourage you to look at our filings with the SEC for a full disclosure of the risks associated with the Company....

...Lou Scafuri - Syneron Medical Ltd. - CEO My name is Lou Scafuri. I am the CEO of Syneron Medical. I am here to present both Syneron Medical and Candela. Just recently, approximately ## days ago we announced our merger and this presentation will contain forward-looking statements. Today I will do the bulk of the presentation and joining me are [Gerry] Puorro, who is the CEO of Candela Medical, and Fabian Tenenbaum, who is the CFO of Syneron. We have got exciting news. The combination of both Syneron and Candela represents a global leader in aesthetic technology. We have a very comprehensive product portfolio including Syneron's proprietary elos technology, combination of light and energy or [FN] energy, and Candela, who is a pioneer of light-based laser technology, an innovator for over ## years. We have a balanced mix of sales to both the core and the non-core physicians, as well as the best worldwide distribution system and support network with sales in close to ## countries with ##% of...

...Jeffrey Mathews Scholastic Corp - VP IR Dick Robinson Scholastic Corp - Chairman & CEO Maureen O'Connell Scholastic Corp - Chief Administrative Officer & CFO Margery Mayer Scholastic Corp - President Scholastic Education Judy Newman Scholastic Corp - President Scholastic Book Clubs Hugh Roome Scholastic Corp - President Scholastic Int'l Growth Areas & Consumer Magazines. CONFERENCE CALL PARTICIPANTS...

...Jeff Elliott - UBS - Analyst Good afternoon, and welcome, again, to the UBS Global Life Sciences Conference. I am Jeff Elliott; I am the small and mid-cap US biotech analyst here at UBS. It's my pleasure today to introduce Dyax. With us today is Mr. Gustav Christensen, President and Chief Executive Officer. Immediately following the presentation, there will be a breakout session downstairs in the Alvin Room, so if you would please hold your questions until then. And with that, I will turn it over to Gustav. Gustav Christensen - Dyax Corp. - President and CEO Thank you very much, Jeff, for the kind introduction, and thank you, to you, for coming to listen to the Dyax presentation. It's always a pleasure to have the opportunity to speak about Dyax. And at this time, it's especially exciting for us because we are nearing an important date in our history that could help us transform the Company. So, I do have to show you the Safe Harbor statement, because we will be making forward-looking statements....

... going to get started with the next presentation. We're lucky enough to have Alcon here, and we have the CEO of Alcon, Kevin Buehler. He's been the CEO since, I believe, around April, but he's been with the Company for ##-ish years in all different roles. So, he really knows this Company very well. And certainly, stocks have done well since you joined, so I don't know -- so. But I thank you very much for joining us and we look forward to the your presentation. We'll do the breakout downstairs for questions and stuff. Thanks. Kevin Buehler - Alcon Inc. - President and CEO Thanks, Mark. Good afternoon to everybody. It looks like we're the lunchtime entertainment event, so enjoy your lunch. We've got the traditional Safe Harbor statement and then we can get right into the presentation. Obviously, this has been an interesting time to take over as CEO starting in April and -- with some of the environmental factors that we've had to deal with. But...

...Don Morel West Pharmaceutical Services - Chairman and CEO Bill Federici West Pharmaceutical Services - CFO C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Martin Molyneaux - FirstEnergy Capital - Analyst We started following Niko Resources when it had a market capitalization of $## million. Today Niko's market cap is $#.# billion. Niko currently has a portfolio of properties in various stages of evolution between India, Bangladesh, Kurdistan, Pakistan, Madagascar, Indonesia and most recently in Trinidad. Niko is participating in what we believe is the biggest natural gas discovery in the world in the last decade. Natural gas production at D# came on stream in April, ramping up to target initial production of #.# Bcf a day. Most importantly, all of this production at the moment is only coming from about #% of the entire block. Joining us from Niko is Ed Sampson, who is the Chairman of the Board, President and CEO. Ed Sampson - Niko Resources - President and CEO Martin, thank you, FirstEnergy, Societe Generale. Ladies and gentlemen, thank you for having us here this morning and listening to Niko's story. Obligatory forward statements. After...

...Operator Hello and welcome to the John Wiley & Sons investor meeting webcast. We have just a few announcements before we begin. The slides will advance automatically throughout the presentation. (Operator Instructions). I would now like to turn the call over to Mr. Brian Campbell, Director, Investor Relations. Brian Campbell Goodmorning,everyone,andwelcometoJohnWiley&Sons'####investorconference.OnbehalfofWileycolleaguesworldwide, I want to thank you for joining us, those of you in the room as well as on the webcast. We have quite a turnout. At the conclusion of the presentation, we're going to have a Q&A session, so I just ask that you hold your questions until then. Also, if you could switch off all BlackBerrys and cell phones, that would be greatly appreciated. Without further ado, I would like to introduce Will Pesce, President and CEO. Will Pesce Thank you, Brian. Good morning, everyone, and thank you for taking the time to be with us today. To those of you who have been long-term shareholders,...

...Rod Bourgeois - Analyst Jason Kupferberg UBS - Analyst Glen Greene Oppenheimer - Analyst Ashwin Shirvaikar Citigroup - Analyst Gary Bisbee Barclays Capital - Analyst Jim MacDonald First Analysis - Analyst James Kissane Bank of America Securities, Merrill Lynch - Analyst Tim Willi Wells Fargo Securities - Analyst Chris Mammone Deutsche Bank - Analyst Mark Marcon Robert W Baird - Analyst Gary Christian Credit Suisse - Analyst Michael Baker Raymond James - Analyst Franco Turrinelli William Blair & Company - Analyst Tien-Tsin Huang JP Morgan - Analyst OVERVIEW...

...There has been only one new agent to treat patients with hyperuricemia and gout approved in the United States in the last ## years. So even though it is a very large market, we see it as a wide-open market in terms of opportunity for new therapeutic agents. The other interesting upside potential down the road is that hyperuricemia has been linked very closely with increased cardiovascular risk, and has recently been demonstrated that you can in fact lower blood pressure in new onset hypertensive adolescents by lowering uric acid. So there is a close-tie in between elevated uric acid and potential increased cardiovascular events. ##% of patients with gout and hyperuricemia are under-excreters of uric acid. They don't clear enough uric acid through their kidney. As you'll see, our drug specifically targets this issue and increases excretion back up to normal levels and above. And we now know that in fact defects in renal transporters, specifically genetically linked defects, are the primary...

...Steven Crowley Craig-Hallum Capital - Analyst Tony Brenner Roth Capital Partners - Analyst Marco Rodriguez Stonegate Securities - Analyst Steve O'Neil Hilliard Lyons - Analyst Brian Jeep Sidoti & Company - Analyst Travis Williams Stephens - Analyst Peter Coil - Private Investor P R E S E N T A T I O N...

... Officer from ViroPharma. Please note that the Q&A breakout session will be held in the [Euris] room directly following the presentation. Thank you. Charlie Rowland - ViroPharma, Inc. - VP, CFO Thanks, Lee. Welcome, everybody, to our presentation. I will be making forward-looking statements during this presentation, and I recommend everyone look at our recent Ks and Qs to get a more thorough discussion of those risks and uncertainties surrounding our business. So, I'm going to spend almost the entire presentation talking about Cinryze. This is our product for HAE. It is the foundation of our company, going forward, in terms of growth. It is basically the cornerstone for our expansion geographically. Also, we will be developing the product over time for other indications, which will be very exciting in terms of long-term growth delivery from the company. So,...

...Bob Labick CJS Securities - Analyst Tony Cristello BB&T Capital Markets - Analyst Bill Armstrong CL King & Associates - Analyst Scott Ciccarelli RBC Capital Markets - Analyst Craig Kennison Robert W. Baird & Company, Inc. - Analyst Scott Stember Sidoti & Company - Analyst Gary Prestopino Barrington Research Associates, Inc. - Analyst Jordan Hymowitz Philadelphia Financial - Analyst Justin Boisseau Gates Capital Management - Analyst P R E S E N T A T I O N...

...Rod Bourgeois - Analyst Jason Kupferberg UBS - Analyst Glen Greene Oppenheimer - Analyst Ashwin Shirvaikar Citigroup - Analyst Gary Bisbee Barclays Capital - Analyst Jim MacDonald First Analysis - Analyst James Kissane Bank of America Securities, Merrill Lynch - Analyst Tim Willi Wells Fargo Securities - Analyst Chris Mammone Deutsche Bank - Analyst Mark Marcon Robert W Baird - Analyst Gary Christian Credit Suisse - Analyst Michael Baker Raymond James - Analyst Franco Turrinelli William Blair & Company - Analyst Tien-Tsin Huang JP Morgan - Analyst P R E S E N T A T I O N...

...Robert Farago Schroders Private Bank - Analyst Rupert Heggs Rathbone Investment Management Ltd - Analyst P R E S E N T A T I O N...

...Chris Woronka Deutsche Bank - Analyst Felicia Hendrix Barclays Capital - Analyst Will Marks JMP Securities - Analyst Jake Hindelong Monness, Crespi, Hardt & Co. - Analyst David Hargreze Sterne, Agee - Analyst P R E S E N T A T I O N...

...Jawad Hasan - UBS - Analyst Good afternoon and thank you again for attending the #### UBS Global Life Sciences conference. My name is Jawad Hasan and I am happy to be your host for this session. Our next presentation will be from Jerry McMahon, who is Chairman and CEO of Poniard Pharmaceuticals. Immediately after the presentation, there will be a breakout session in the Juilliard room, which is on the conference level one floor below. Thank you. Jerry McMahon - Poniard Pharmaceuticals, Inc. - Chairman and CEO Thank you very much for the kind invitation to present today about Poniard Pharmaceuticals. Various statements I will be making are forward-looking and I ask that you consult our SEC filings on record at Poniard.com. So we have an exciting time this year. This is a business that has been working pretty diligently over the last few years to really create what we think will be a significant value later this year and it is around the development of a product we call picoplatin, which...

...Jawad Hasan - UBS - Analyst Good afternoon and thank you again for attending the #### UBS Life Sciences Conference. My name is Jawad Hasan and I'm happy to be your host for this session. Our next presentation is from Glyn Edwards, who is the Chief Executive Officer of Antisoma. Immediately following the presentation, there will be a breakout session in the Juilliard Room on the conference level, which is directly one floor below. Thank you. Glyn Edwards - Antisoma plc - CEO Thank you very much. Welcome to the Antisoma presentation. First, I'd like to draw your attention to our Safe Harbor statement. We are a cancer-focused biotech company listed on the London Stock exchange. We have offices in Cambridge, Massachusetts and in London with about ## people in the Company. We're at a very exciting time as we start to prepare for commercialization of our drugs. We've spent what seems to me a great deal of time in the development phase of these products and now with two drugs in Phase III we're...

...Andrew Peters - UBS - Analyst/Moderator Good morning. Welcome to the final day of the UBS Global Life Sciences Conference. I am Andrew Peters, and I'm on the biotech team here at UBS. It's my pleasure to introduce The Medicines Company presenting this morning. With us is Mr. John Kelley, President and COO. Immediately following the presentation, there'll be a breakout session downstairs in the Juilliard room. So if you could, please hold your questions to then. With that, let me turn it over to John. John Kelley - The Medicines Co. - President, COO Thank you, Andrew, and thanks to UBS for inviting us to this conference. I want to thank all of you for your interest in The Medicines Company and attending the session this morning. I'm John Kelley. I am the President and Chief Operating Officer of The Medicines Company. During my presentation this morning, I will be making forward-looking statements. There are inherent risks in those statements. I refer you to our recent SEC filings for a more...

...Keyur Parekh - UBS - Analyst Good morning and welcome to the UBS Global Life Sciences conference. I'm Keyur Parekh and I cover the U.S. large-cap pharmaceutical stocks. It is my pleasure to introduce Merck & Co. today. Representing Merck will be Ken Frazier, President, Global Human Health. And he is joined by Eva Boratto, Vice President Investor Relations, and Carol Ferguson, Director Investor Relations. Immediately following the presentation will be a breakout session in the Broadway room at the conference level. I would appreciate if you can hold on to your questions until then. With that, let me pass it over to Ken. Ken Frazier - Merck & Co. Inc. - President Global Human Health Thank you, Keyur. Good morning. It's my pleasure to be here this morning to share with you what's going on these days at Merck, particularly from a commercial perspective. And I look forward to joining -- adjourning from this room later on to answer your questions in hopefully an adjoining room. So with that,...

...Raj Mehan Steelcase Inc. - Director, IR Jim Hackett Steelcase Inc. - President, CEO David Sylvester Steelcase Inc. - CFO Terry Lenhardt Steelcase Inc. - VP, North American Finance C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Maria Salerno Comtech Telecommunications Corp. - IR Fred Kornberg Comtech Telecommunications Corp. - President & CEO Michael Porcelain Comtech Telecommunications Corp. - SVP & CFO C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Chris Growe Stifel Nicolaus - Analyst Ken Goldman JPMorgan - Analyst Eric Serotta Consumer Edge - Analyst Eric Katzman Deutsche Bank - Analyst Mitch Pinheiro Janney Montgomery Scott - Analyst OVERVIEW...

...Gregory Steinberg American Greetings Corp. - Treasurer & Director of IR Zev Weiss American Greetings Corp. - CEO Steve Smith American Greetings Corp. - SVP & CFO CONFERENCE CALL PARTICIPANTS...

...Chris Hall Rite Aid Corporation - SVP, Strategic Business Development Mary Sammons Rite Aid Corporation - Chairman, CEO Frank Vitrano Rite Aid Corporation - CAO, CFO John Standley Rite Aid Corporation - President, COO CONFERENCE CALL PARTICIPANTS...

...Steve Salberta Boenning & Scattergood - Analyst Jeff Kvaal Barclays Capital - Analyst Jonathan Kofsky Sanford Bernstein - Analyst Nim Park Goldman Sachs - Analyst OVERVIEW...

...Elana Holzman Teva Pharmaceutical Industries Ltd. - Senior Director of IR Bill Marth Teva Pharmaceutical Industries Ltd. - President and CEO Warren Olanow Mount Sinai School of Medicine - Chairman of Dept. of Neurology CONFERENCE CALL PARTICIPANTS...

...Gregory Steinberg American Greetings Corp. - Treasurer & Director of IR Zev Weiss American Greetings Corp. - CEO Steve Smith American Greetings Corp. - SVP & CFO C O N F E R E N C E C A L L P A R T I C I P A N T S...

...Chris Hall Rite Aid Corporation - SVP, Strategic Business Development Mary Sammons Rite Aid Corporation - Chairman, CEO Frank Vitrano Rite Aid Corporation - CAO, CFO John Standley Rite Aid Corporation - President, COO C O N F E R E N C E C A L L P A R T I C I P A N T S...